Skip to main content
. Author manuscript; available in PMC: 2017 May 15.
Published in final edited form as: Int J Cardiol. 2016 Mar 2;211:14–21. doi: 10.1016/j.ijcard.2016.02.139

Table 2. Heart failure with preserved ejection fraction (HFpEF) specific characteristics and pharmacotherapy.

Disease-specific characteristics
 NYHA Class II 11 (52%)
 NYHA Class III 8 (38%)
 NYHA Class IV 2 (10%)
 Diabetic 10 (48%)
 Hypertensive 17 (81%)
Echocardiographic and Doppler analysis
 Left ventricular ejection fraction (%) 61 ± 1
 E-wave velocity (cm/s) 89 ± 8
 A-wave velocity (cm/s) 100 ± 11
 E/A ratio 1.14 ± 0.19
 E/E′ (medial) 19 ± 3
 E/E′ ratio (lateral) 13 ± 2
 Mitral E-wave deceleration time (ms) 216 ± 19
  Functional capacity
 Six min walk (m) 414 ± 68
 Gait speed (m/s) 0.94 ± 0.07
  Medications
 β blocker 9 (43 %)
 ACEi or ARB 8 (38%)
 Loop diuretic 20 (95%)
 Aldosterone antagonist 14 (67%)
 Statin 16 (76%)
 Nitrates 5 (24%)

New York Heart Association, NYHA.